Granulopoiesis-stimulating factors given after chemotherapy probably lower infection risks for solid tumor patients, but a systematic review published on November 17 in the Cochrane Database of Systematic Reviews shows they likely cause a large increase in bone pain.
Solid tumors represent roughly 90% of adult cancers, forming in tissues like the breasts, lungs, bones, and liver. Chemotherapy treats these masses but routinely suppresses bone marrow activity. This suppression slows blood cell production, leading to neutropenia, heightened infection risks, and compromised survival rates.
To counteract this, clinicians administer granulopoiesis-stimulating factors, which include granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF). These medicines stimulate the body to generate infection-fighting white blood cells before counts drop dangerously low.
Mina Ma, Minyan Yang, and Yanan Wu led a team of eleven researchers across institutions including Technical University Munich and Lanzhou University to evaluate these supportive therapies. Their team searched CENTRAL, MEDLINE, and Embase through June 2025 for relevant clinical data. The review identified 26 randomized controlled trials encompassing 5,320 participants with solid tumors.
Primary preventative administration of G-CSF or GM-CSF likely reduces infection risk compared to no prophylaxis, according to data from 7 studies involving 915 people. However, the review found that prophylactic use may result in little to no difference in overall survival, based on 3 studies of 537 participants. Freedom from treatment failure similarly showed little to no difference across the evaluated cohorts.
In Plain English: The Clinical Takeaway
- Fewer Infections: Taking these white blood cell boosters proactively after chemotherapy makes bacterial and viral infections less likely.
- Survival Impact: Current evidence shows these medications probably do not extend the overall length of time patients live after their diagnosis.
- Physical Trade-offs: Patients face a notably higher probability of experiencing bone pain as an adverse side effect.
Evaluating Survival and Adverse Events in Clinical Trials
The 26 trials examined by Ma and colleagues compared primary prophylaxis against placebo or no treatment. Across 11 studies involving 3,001 participants, researchers observed little to no difference in all-cause mortality during chemotherapy between the study groups. The evidence for these mortality outcomes is rated as moderate certainty.
Adverse events remain a central consideration for oncologists managing chemotherapy schedules. Primary prophylaxis with G-CSF probably results in a large increase in the risk of bone pain, according to pooled data from 10 studies with 3,152 participants. Individual trial reports highlighted unexpected utilization metrics, such as one study noting a longer average hospitalization duration of 9.7 days versus 5.2 days for patients receiving specific interventions.
Quality of life metrics were entirely absent from the reporting of all 26 included studies. This omission leaves an important clinical gap in understanding how patients subjectively experience the balance between reduced infections and increased bone pain.
| Outcome Evaluated | Number of Studies | Participant Count | Statistical Finding |
|---|---|---|---|
| Risk of Infection | 7 | 915 | Likely reduction (RR 0.64) |
| Overall Survival | 3 | 537 | Little to no difference (HR 0.85) |
| All-Cause Mortality | 11 | 3,001 | Little to no difference (RR 0.92) |
| Risk of Bone Pain | 10 | 3,152 | Large increase (RR 3.55) |
Despite evaluating thousands of patients, the research team emphasized that significant uncertainties remain regarding optimal supportive care. It is still unclear whether GM-CSF provides clinical benefits comparable to G-CSF, as direct comparative data are sparse. Researchers cannot yet confirm whether utilizing these growth factors helps individuals live longer when both study and control groups adhere to identical chemotherapy regimens.
The certainty of the current evidence ranges from moderate to low. Limitations stem from open-label study designs where personnel and participants knew their treatment allocations, wide outcome variations across small trial sizes, and differing dosing strategies implemented across various solid tumor types.
Future high-quality, double-blind randomized trials are required to refine these clinical parameters. Until those investigations conclude, medical teams must weigh the documented reduction in infection against the well-established risk of bone pain when planning supportive care for solid tumor treatments.
References
- Prophylactic granulopoiesis-stimulating factors for people with solid tumors undergoing cancer treatment. Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.CD015656.pub2